Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Melanoma and other skin tumours

4441 - KEYNOTE-022 Part 3: Phase 2 Randomized Study of 1L Dabrafenib (D) and Trametinib (T) Plus Pembrolizumab (Pembro) or Placebo (PBO) for BRAF-Mutant Advanced Melanoma

Date

22 Oct 2018

Session

Proffered paper session - Melanoma and other skin tumours

Presenters

Paolo Ascierto

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

P.A. Ascierto1, P.F. Ferrucci2, R. Stephens3, M. Del Vecchio4, V. Atkinson5, H. Schmidt6, J. Schachter7, P. Queirolo8, G.V. Long9, A.M. Di Giacomo10, I. Svane11, M. Lotem12, G. Bar-Sela13, F. Couture14, B.P. Mookerjee15, R. Ghori16, N. Ibrahim16, B. Homet Moreno16, A. Ribas17

Author affiliations

  • 1 Melanoma, Cancer Immunotherapy And Development Therapeutics Unit, Istituto Nazionale Tumori Fondazione G. Pascale, 80131 - Napoli/IT
  • 2 Oncology, Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 3 Medical Oncology, Auckland City Hospital, Auckland/NZ
  • 4 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 5 Medical Oncology, Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Brisbane/AU
  • 6 Oncology, Aarhus University Hospital, 8000 - Aarhus C/DK
  • 7 Oncology, Ella Lemelbaum Institute for Melanoma, Sheba Medical Center at Tel HaShomer, Cancer Center (Oncology Institute), Ramat Gan/IL
  • 8 Oncologia Medica 2, IRCCS San Martino-IST, Genova/IT
  • 9 Medical Oncology, Melanoma Institute Australia, University of Sydney, 2060 - North Sydney/AU
  • 10 Medical Oncology, Center for Immuno-Oncology, University Hospital of Siena, 53100 - Siena/IT
  • 11 Oncology, Herlev Hospital, University of Copenhagen, Herlev/DK
  • 12 Medical Oncology, Sharett Institute of Oncology, Hadassah Hebrew Medical Center, Jerusalem/IL
  • 13 Oncology, Rambam Health Care Campus, 31096 - Haifa/IL
  • 14 Hematology, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec/CA
  • 15 Oncology Clinical Development, Novartis, 07906 - East Hanover/US
  • 16 Medical Oncology, Merck & Co., Inc., Kenilworth/US
  • 17 Medical Oncology, Ronald Reagan UCLA Medical Center, 90095-1781 - Los Angeles/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4441

Background

Pembro + D + T had promising antitumor activity and acceptable tolerability in phase 1 of KEYNOTE-022 (NCT02130466).

Methods

In the double-blind phase 2 part of KEYNOTE-022, pts with treatment (tx)-naive BRAFV600E/K-mutant stage III/IV melanoma were randomly assigned (stratified by ECOG PS [0/1)]; LDH level [>1.1 vs ≤ 1.1× ULN]) to pembro 2 mg/kg Q3W + D 150 mg BID + T 2 mg QD or PBO + D + T. Strata with ECOG PS 1 and either LDH level were combined due to small numbers. Primary end point was PFS. Significance requirements to reject null hypothesis at 1-sided 0.025 type I error: ∼74 PFS events for 80% power; observed HR ≤ 0.62. Additional end points included ORR, DOR, TTR, and OS. Data cutoff: Feb 15, 2018.

Results

Of 60 pts in each arm, most baseline characteristics were balanced (stage IV disease, 98% in pembro + D + T vs 95% in PBO + D + T; ECOG PS 0, 80% both; LDH >1.1× ULN, 45% vs 43%). Median follow-up for both arms was 9.6 mo (range 2.7-23.4). 67% vs 70% received ≥12 mo tx. Median PFS was 16.0 mo (95% CI 8.6-21.5) with pembro + D + T vs 10.3 mo (95% CI 7.0-15.6) with PBO + D + T; HR, 0.66; P = 0.04287; 12-mo PFS rates were 59% vs 45%. ORR was 63% vs 72%; CR rates were 18% vs 13%. Median TTR was 2.8 mo in each arm; median DOR was 18.7 mo (range 1.9+ to 22.1) vs 12.5 (2.1-19.5+). More patients (60%) on pembro + D + T had responses lasting ≥18 mo vs PBO + D + T (28%). OS rates at 12 mo were 80% vs 73%. Any grade (G) treatment-related AEs (TRAEs) occurred in 95% vs 93% and G3-5 TRAEs occurred in 58% vs 27% of pts. G3-5 TRAEs occurring in ≥ 5% of pts were pyrexia (10% vs 3%), increased ALT (7% vs 5%), increased AST (8% vs 5%), increased GGT (7% vs 5%), rash (5% vs 2%), and neutropenia (2% vs 5%). 40% vs 20% of pts discontinued any of the 3 study tx due to TRAEs, and 1 pt died due to a TRAE (pneumonitis) in the pembro + D + T arm. Immune-mediated AEs occurred in 43% vs 13% of pts, most commonly pneumonitis (15% vs 2%), hypothyroidism (8% vs 2%), skin disorders (7% vs 2%), hyperthyroidism (5% vs 0%), and uveitis (5% vs 3%); most resolved with tx discontinuation/modification.

Conclusions

Pembro + D + T vs PBO + D + T demonstrated numerically longer PFS and DOR and a higher rate of G3-5 TRAEs in pts with tx-naive BRAFV600E/K-mutant advanced melanoma.

Clinical trial identification

NCT02130466.

Legal entity responsible for the study

Merck & Co., Inc.

Funding

Merck & Co., Inc.

Editorial Acknowledgement

Medical writing and/or editorial assistance was provided by Doyel Mitra, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

P.A. Ascierto: Advisory board member: BMS, Roche-Genentech, MSD, Array, Novartis, Amgen, Merck Serono, Pierre Fabre, Incyte, Genmab, Newlink Genetics, Medimmune, Syndax, AstraZeneca; Research funding: BMS, Roche-Genentech, Array. P.F. Ferrucci: Advisory board member: BMS, Novartis, MSD; Research funding: BMS, MSD; Honoraria, travel expenses, accommodations: BMS, Novartis, MSD, Roche. R. Stephens: Honoraria, travel expenses: MSD NZ. M. Del Vecchio: Consultant, advisor, research funds: Bristol-Myers Squibb, Roche-Genentech, GlaxoSmithKline, Merck Sharp and Dohme. V. Atkinson: Advisory board member: BMS, MSD, Novartis, Merck Serono, Pierre Fabre; Speakers’ bureau: BMS, MSD, Novartis, Roche; Honoraria: BMS, MSD, Novartis; Travel expenses: BMS, MSD. H. Schmidt: Advisory board member: BMS, MSD, Incyte, Roche; Speakers’ bureau: BMS, Novartis; Research funding: MSD; BMS. J. Schachter: Honoraria, consultant/advisory, travel, accomodations, expenses: BMS, MSD. P. Queirolo: Advisory board member, speakers' bureau, gonoraria, travel expenses, accommodations: BMS, Roche, Novartis, MSD. G.V. Long, A.M. Di Giacomo: Advisory board member: Incyte, GSK, Pierre Fabre; Honoraria: BMS, Roche, MSD; Travel expenses, including accommodations: BMS, Roche. I. Svane: Honoraria/Consulting fees: Roche, Novartis, Merck, MSD, Celgene, Incyte, Pfizer, BMS, AstraZeneca, TILT Bio, IO Biotech; Stock (co-founder): IO Biotech. M. Lotem: Advisory board member: Merck; Honoraria: Merck, BMS; Travel expenses, accommodations: Merck, BMS, Novartis. G. Bar-Sela: Research funding: Merck. B.P. Mookerjee: Employee: Novartis; Stock: Novartis, GSK, AstraZeneca. R. Ghori, N. Ibrahim, B. Homet Moreno: Employee: Merck & Co., Inc. A. Ribas: Stock ownership: Lutris, PACT, Tango; Advisory board member: Advaxis, Arcus, BioncoTech, Compugen, CytomX, Five Prime, FLX-Bio, ImaginAb, Isoplexis, Kite-Gilead, Rgenix; Honoraria: Amgen, BMS, Chugai, Genentech, Merck, Novartis, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.